Article

ASCRS 2020: Clinical trial results of KP1-121 0.25% for dry eye treatment

Author(s):

Alex Delaney-Gesing
Conferences|ASCRS

Edward Holland, MD, director of Cornea Services at Cincinnati Eye Institute, speaks with Ophthalmology Times' David Hutton on the results of a clinical trial using KP1-121 0.25% (loteprednol etabonate) for dry eye treatment during the 2020 ASCRS virtual meeting.

 

See more ASCRS coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
Related Content
Aldeyra submits third new drug application for reproxalap for the treatment of dry eye disease
June 17th 2025

Aldeyra submits third new drug application for reproxalap for the treatment of dry eye disease

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Ophthalmologists present data on perfluorohexyloctane eye drops
June 6th 2025

Ophthalmologists present data on perfluorohexyloctane eye drops

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease
May 29th 2025

FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease

Iolyx Therapeutics reports phase 2 results for ILYX-002 in autoimmune-associated dry eye disease
May 27th 2025

Iolyx Therapeutics reports phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

© 2025 MJH Life Sciences

All rights reserved.